A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.

Karim Fizazi,Xavier Maldonado,Stéphanie Foulon,Guilhem Roubaud,Raymond S. McDermott,Aude Flechon,Bertrand F. Tombal,Stéphane Supiot,Dominik Berthold,Philippe Ronchin,Gabriel Kacso,Gwenaelle Gravis,Fabio Calabrò,J.-F. Berdah,Ali Hasbini,Marlon Silva,Antoine Thiery-Vuillemin,Isabelle Rieger,Marie Laure Tanguy,Alberto Bossi

A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.

2021

5000Background: Historically, androgen deprivation therapy (ADT) was the standard of care (SOC) for men with mCSPC. Since 2015, combining ADT with either docetaxel, novel hormonal therapies, or rad...

Keywords:

local radiotherapy
Docetaxel
Prednisone
Castration-sensitive prostate cancer
Medicine
standard of care
Internal medicine
Oncology
Androgen deprivation therapy
Factorial experiment
Abiraterone acetate

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations